Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661492 · ClinicalTrials.gov registry record · Phase 2
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00661492 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 115 participants.
The verdict
NCT00661492, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment date to the date the patient is first recorded as having disease progression, even in patients who discontinue study treatment early due to toxicity.
Interventions
- DRUG cetuximab
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661492
The ClinicalTrials.gov registry entry for NCT00661492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cetuximab is the first listed.
NCT00661492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661492 about?
NCT00661492 is a clinical study titled "Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)". To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment date to the date the pati...
What is the current status of trial NCT00661492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2008-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00661492?
The interventions under investigation include: cetuximab (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00661492?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.